Uncategorized

No img

Tevard Biosciences Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ — Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies for rare and severe genetic diseases, today announced the appointment of Gopi Shanker, Ph.D., as Chief Scientific Officer and as a member of the company’s executive leadership team. With more than 20 years of experience in industry and […]

Leer Más
No img

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies

CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ — Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies. Read More

Leer Más

Two promising neuroscience startups awarded “Golden Tickets”

Photo Caption: Shared laboratory space at LabCentral in Kendall Square Cambridge, Massachusetts Boston-based startups Tevard Biosciences and QurAlis announced as winners of the Pfizer Neuroscience Golden Ticket Program   In June 2018, Pfizer Kendall Square opened a call for interested U.S. startup companies focused on neuroscience to submit non-confidential proposals for a Pfizer-sponsored LabCentral “Golden […]

Leer Más